Medtronic has announced plans to double both the physical size and headcount of its London office, which focuses on developing cutting-edge artificial intelligence (AI) and digital technologies for robotic surgery. This expansion marks a significant commitment to advancing medical innovation.
Multimillion-Dollar Investment Aligns with NHS Goals
This growth is part of a multimillion-dollar investment in the U.K. that will extend over the next five years. Medtronic aims to support several objectives outlined in the National Health Service’s (NHS) decade-long plan, which officially began this summer.
Largest Global Center in East London Tech City
The research and development office is located in London’s “Silicon Roundabout,” also known as East London Tech City. It will expand to 25,000 square feet and employ more than 200 people. This expansion will make it Medtronic’s largest global center for AI and surgical robotics.
George Murgatroyd, Medtronic’s general manager for digital surgical technologies, stated, “The future of surgery is increasingly digital. Our investment reflects the significant talent and innovation here in the UK, including in AI, and is a statement of intent to transform healthcare outcomes for surgeons and patients worldwide.”
Innovations and Collaborations at the Center of Digital Excellence
The London hub, hailed as a center of digital excellence, has previously contributed to AI systems that analyze surgical procedures and offer real-time decision support. It also develops telesurgery programs and features a mock operating theater where healthcare professionals test new robotic platforms.
“Placing ourselves in the beating heart of London’s tech hub, probably the most innovative square mile in Europe, is key to building the future of digitally-enabled healthcare,” Murgatroyd added.
Medtronic’s Commitment Stands Out Amid Industry Pullback
As per Fierce Biotech, Medtronic’s expansion contrasts with recent decisions by several big pharmaceutical companies to scale back or relocate their U.K.-based R&D operations. For instance, Merck & Co. recently canceled a $1.3 billion London project and moved its research elsewhere. Similarly, AstraZeneca paused a $271 million investment in Cambridge, while Eli Lilly reconsidered a $378 million biotech incubator plan. Sanofi also froze its U.K. R&D spending. These cutbacks largely relate to an NHS policy requiring drugmakers to pay back a greater share of sales from newer branded medicines.
Strengthening Local Partnerships to Drive Innovation
Medtronic plans to continue fostering local collaborations for robotic surgery system design. The company already partners with prominent hospitals such as Imperial College, King’s College, University College London Hospitals, and Guy’s and St. Thomas’. These collaborations include work on the Hugo soft tissue robot, the AI-powered GI Genius platform, and PillCam endoscopy devices.
“This is a transformative moment for surgical innovation within the NHS,” said Sanjay Purkayastha, M.D., a bariatric surgeon at Imperial College Healthcare NHS Trust. “AI-powered technologies are no longer future concepts in surgery; they are here and will redefine how we care for patients. By working with partners like Medtronic, we can accelerate the adoption of digital tools in the operating theatre and set a new standard for precision, training, and patient outcomes across the NHS.”
Expanding Beyond London: Partnership in Manchester
Beyond London, Medtronic recently renewed its partnership with the Manchester University NHS Foundation Trust. This U.K.-first agreement will focus on co-developing AI and robotic technologies targeting cardiovascular disease, neuroscience, medical surgery, and diabetes.